1. Happy Thanksgiving from Cafepharma! Our news staff will be off on Thursday, and will be feeding news on a limited basis throughout the holiday weekend. CP Today will return on Monday, November 30. We hope you enjoy this time, and stay safe! — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Alnylam makes case for lumasiran in infants ahead of FDA ruling

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 23, 2020 at 11:02 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    17,952
    Likes Received:
    3
    via Alnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.

    article source